🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 47103J105
- Market Cap
- Mid Cap
- IPO
- 6/11/2021 · $17.00/share
Business: Janux Therapeutics, Inc. is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets.
Company Contact
- CEO
- David Campbell
- CFO
- Tighe Reardon
- Headquarters
- 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA 92130
- Phone
- 858-751-4493